C-Path Welcomes TransPerfect Life Sciences C-Path is proud to welcome TransPerfect Life Sciences as the newest member of its Electronic Clinical Outcome Asse
C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD Diagnosis C-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal De
Regulus Therapeutics Joins PKDOC C-Path is excited to announce that Regulus Therapeutics, Inc. has joined the Polycystic Kidney Disease Outcomes Consortium (PKD
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Joins PKDOC C-Path is excited to announce that Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) has joined its Polycy
C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common Goals Critical Path Institute is pleased to announce the recent collaboration agreement between C-Path and Mobilise-D. By
December 16, 2022 eCOA Consortium and PRO Consortium Announce Publication of Two Open Access Articles C-Path’s eCOA Consortium and PRO Consortium are pleased to announce the publication of two open access articles in the Jour
eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Implementing Numeric Rating and Visual Analog Scales in an eCOA Soluti
eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Survey Investigates Backup Solution Adoption for ePRO Systems” has bee
eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Evaluating the Use of Backup Solutions for ePRO Systems” has been publ
Four PKD Reports Published in CJASN C-Path and PKDOC are excited to announce that four reports summarizing Sessions 1, 2, and 3B from the 2021 PKD Regulatory Summit h